Overview

A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of CERC-006 in adults (aged 18-31 years) with active, moderate to severe complex lymphatic malformations.
Phase:
Phase 1
Details
Lead Sponsor:
Cerecor Inc